Profund Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Profund Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,007	Closed	-$714K	–	1097
2023 Q2	$714K	Buy	7,007 +2,401	+52%	+$227K	0.04%	403
2023 Q1	$419K	Buy	+4,606	New	+$270K	0.03%	564
2021 Q4	–	Sell	-2,532	Closed	-$255K	–	1419
2021 Q3	$255K	Sell	2,532 -231	-8%	-$27.1K	0.01%	1077
2021 Q2	$391K	Buy	+2,763	New	+$312K	0.01%	843
2021 Q1	–	Sell	-1,825	Closed	-$226K	–	1372
2020 Q4	$226K	Buy	+1,825	New	+$240K	0.01%	1028
2020 Q3	–	Sell	-1,960	Closed	-$306K	–	1015
2020 Q2	$306K	Sell	1,960 -127	-6%	-$19.3K	0.02%	590
2020 Q1	$301K	Sell	2,087 -221	-10%	-$42.7K	0.02%	496
2019 Q4	$472K	Buy	+2,308	New	+$421K	0.02%	642
2018 Q4	–	Sell	-3,590	Closed	-$294K	–	1474
2018 Q3	$294K	Buy	+3,590	New	+$253K	0.01%	1215

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Profund Advisors's RETA Position: Q3 2023 in Review

Profund Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 7,007 shares — an estimated $714K sold.

Profund Advisors first reported a position in RETA in Q3 2018 and held it in 9 quarters. The position peaked at $714K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Profund Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Profund Advisors sold 7,007 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $714K.
Profund Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 9 quarters.
Profund Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $714K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Profund Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.